BTC Health Ltd Registered · ASX:BTC
BTC Health Ltd Registered — BTC Health — Shareholder Meeting (November 2022)
25 slides from BTC Health Ltd Registered's shareholder meeting presentation, Nov 29, 2022
Slide 1: Annual General Meeting 29 November 2022
For personal use only Annual General Meeting 29 November 2022 www.btchealth.com.au (ASX: BTC)
Slide 2: BTC health - Board of Directors
BTC health - Board of Directors For personal use only Dr. Richard Treagus Mr. Jonathan Pilcher Mr. Bruce Hewett Ms. Felicity McNeill Mr. Brendan York Mrs. Sharon Papworth Executive Chairman Director, Chair Audit Director Director Director CFO & Company Committee Secretary
Slide 3: Disclaimer
Disclaimer For personal use only Summary information This Presentation contains summary information about BTC health, and its activities current as at 29/11/2022. The information in the presentation is of a general nature and does not purport to be complete or comprise all information which a shareh
Slide 4: Core Business Focus
Core Business Focus For personal use only Medical Devices Surgical Equipment and Consumables Speciality Pharmaceuticals • BTC health (through its investee companies), invests in high growth specialised medical product companies. • All 3 product segments provide opportunity for attractive sales and m
Slide 5: Growth via Partnering and Acquisitions
Growth via Partnering and Acquisitions For personal use only Company BTC Consumables Neola Medical Mediplus Alteco distribution changes to BTC brand launched distribution distribution agreement health agreement agreement July 2017 May 2019 Nov 2019 Aug 2020 Feb 2021 June 2021 Sept 2021 May 2022 Aug
Slide 6: Portfolio and Pipeline
Portfolio and Pipeline For personal use only Launched products Product pipeline Launched products Product pipeline Remaining product Launched products Product pipeline pipeline in discussion Remaining product Remaining product pipeline in discussion pipeline in discussion Medical Devices Surgical Eq
Slide 7: New Products - FY23
New Products - FY23 For personal use only Easy Reach - a complementary product range • An innovative solution designed by international hip surgeons. • Enables donning of underwear following hip replacement and other forms of surgery that restrict patient mobility. • Market size is attractive - 49,7
Slide 8: Business Highlights
Business Highlights For personal use only • Sales to hospitals for the financial year ended 30 June 2022 were $8.2m and grew 12% over pcp. • On-Track to generate double-digit sales to hospital growth in FY23, with September quarter sales up 6% over pcp. • The respiratory product portfolio generated
Slide 9: Sales Performance - FY22 and 1Q23
Sales Performance - FY22 and 1Q23 For personal use only • 12-month rolling sales to Sept ‘22 of $8.3m, grew +9% over pcp. • Sept ‘22 quarter sales to hospital grew 6% over pcp • Elective surgery backlog continues, with hospital staff shortages impacting volume of elective surgeries conducted. • Gove
Slide 10: Sales Profile
Sales Profile For personal use only 25% • Strategy to diversify product offering into Surgical Equipment & Consumables and Specialty Pharma • Opportunity to develop the business in the southern states and NZ
Slide 11: Bronchitol and Aridol - sales update
Bronchitol and Aridol - sales update For personal use only Respiratory Portfolio performance Highlights Sept Qtr 22 Sept Qtr 21 +/- Var Bronchitol 157,210 189,208 -16.9% • Deployment of national sales force calling on respiratory Aridol 128,442 91,846 39.8% Total Respiratory 285,652 281,054 1.6% cli
Slide 12: Scorecard - underlying business YTD Oct '22
Scorecard - underlying business YTD Oct ‘22 For personal use only Sales Earnings 1 • Number of hospitals and clinics: 335 • Sales to wholesalers: $2.8m 3 2 • Sales to hospitals: $2.9m • Gross Margin: 40.2%, Net Margin: 36.6% • OPEX: $1.2m Products 4 • Net Loss: ($0.2m) • Product lines : 60 • Stock o
Slide 13: Business Outlook
Business Outlook For personal use only • A strong focus on delivering double digit sales to hospital growth. Sept ’22 quarter sales to hospitals grew 6% over pcp, despite a relatively soft July. • New clinician onboarding, product launches and an increase in elective surgery rates expected to underp
Slide 14: Annual General Meeting
For personal use only Annual General Meeting 29 November 2022 www.btchealth.com.au (ASX: BTC)
Slide 15: Ordinary Resolution 1: Adoption of Remuneration Report
Ordinary Resolution 1: Adoption of Remuneration Report For personal use only To receive and consider the remuneration report of the Company, and if thought fit, pass the following resolution as a non-binding resolution: “To adopt the Remuneration Report contained in the Directors’ Report for the Com
Slide 16: Ordinary Resolution 2: Election of Felicity McNeill as Director
Ordinary Resolution 2: Election of Felicity McNeill as Director For personal use only To consider and if thought fit to pass the following resolution as an ordinary resolution: “That Ms. Felicity McNeill, who was appointed as director of the Company by the board during the year, will retire at the m
Slide 17: Ordinary Resolution 3: Election of Brendan York as Director
Ordinary Resolution 3: Election of Brendan York as Director For personal use only To consider and if thought fit to pass the following resolution as an ordinary resolution: “That Mr. Brendan York, who was appointed as director of the Company by the board during the year, will retire at the meeting i
Slide 18: Special Resolution 4: Approval 10% placement capacity
Special Resolution 4: Approval 10% placement capacity For personal use only To consider and if thought fit to pass the following resolution as a special resolution: “That, for the purpose of ASX Listing Rule 7.1A and for all other purposes, approval is given for the issue of Equity Securities totali
Slide 19: Annual General Meeting
For personal use only Annual General Meeting 29 November 2022 www.btchealth.com.au (ASX: BTC)
Slide 20: Chairman's Address to Shareholders
BTC health (BTC) - ASX Announcement 29 November 2022 For personal use only Chairman's Address to Shareholders Ladies and gentlemen, I am pleased to provide an update on strategy, our current product portfolio, performance of our investment entities and remarks about the outlook for the company. Stra
Slide 21: For personal use only
Notwithstanding the disruptions of the pandemic, BTC has continued to actively identify and seize relevant opportunities, executing on our strategy of building a healthcare company focused on delivering quality products to private and public hospitals across Australia and New Zealand. The journey co
Slide 22: For personal use only
unmet need in the market for patients following hip or back surgery, where mobility is severely limited. Several products in our pipeline are currently being sourced and evaluated and we expect they will be included in our product catalogue. For personal use only Specialty pharmaceuticals On 30 June
Slide 23: For personal use only
• The respiratory product portfolio generated $1.3m in sales for FY22. Integration of the Pharmaxis products has enabled BTC to commence building of its specialty pharmaceutical product franchise. For personal use only • We secured sales and distribution rights to two new products which will be laun
Slide 24: For personal use only
patients once again return to using a bronchial clearance agent in conjunction with Trikafta. The sales of Aridol are tracking ahead of expectations, responding well to our sales and marketing strategies. Together the combined mannitol franchise, at the end of the September 2022 quarter is For perso
Slide 25: Outlook
Outlook BTC’s investee companies are very well positioned for the next phase of growth. We expect that a relatively higher elective surgery rate, along with new clinician onboarding and new product launches will For personal use only support additional sales and underpin our double-digit revenue gro